|Bid||1.530 x 0|
|Ask||1.545 x 0|
|Day's range||1.510 - 1.560|
|52-week range||1.190 - 2.336|
|PE ratio (TTM)||N/A|
|Earnings date||28 Aug. 2018 - 3 Sep. 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.76|
NEW YORK and MELBOURNE, Australia, June 21, 2018-- Mesoblast Limited today announced key Day 100 survival outcomes of its Phase 3 trial for remestemcel-L, an allogeneic mesenchymal stem cell product candidate, ...
Mesoblast Limited (MESO) (ASX:MSB) today announced that Joseph R. Swedish has joined its Board of Directors. Mr. Swedish has more than two decades of healthcare leadership experience as the CEO for major U.S. healthcare organizations. Prior to joining Anthem, Mr. Swedish was CEO for several major integrated healthcare delivery systems, including Trinity Health and Colorado’s Centura Health.
MELBOURNE, Australia and NEW YORK, May 30, 2018-- Mesoblast Limited today announced strong financial results for the nine months ended March 31, 2018 and provided operational highlights for the third quarter ...
Mesoblast Limited (ASX:MSB) (MESO) today announced the appointment of Josh Muntner as its new Chief Financial Officer, based in New York. Chief Executive Dr Silviu Itescu welcomed the appointment of Mr Muntner stating he would bring substantial U.S. corporate finance, transactional and capital markets experience to Mesoblast. Mr Muntner has accrued 20 years’ experience in healthcare investment banking and corporate finance, and has been involved in a wide range of healthcare-related transactions with approximately $11 billion in value.
NEW YORK and MELBOURNE, Australia, May 29, 2018-- Mesoblast Limited will report financial results for the quarter ended March 31, 2018 in a webcast beginning at 6:30 pm on Wednesday, May 30, 2018 EST; ...
Mesoblast Limited (MESO) (ASX:MSB) today announced that it has entered into a partnership with Cartherics Pty Ltd to develop allogeneic ‘off-the-shelf’ CAR-T cells armed with multiple targeting receptors for use in solid cancers. Off the shelf CAR-T therapies have the potential to reduce costs dramatically and open up this very effective treatment to millions of cancer patients across the world. The initial targets are relapsed ovarian and gastric cancers. Mesoblast and Cartherics will jointly own the intellectual property produced using their combined technologies.
Mesoblast Limited (MESO) (ASX:MSB) today announced that results of the Phase 3 trial evaluating its product candidate MSC-100-IV (remestemcel-L) in children with steroid-refractory acute Graft versus Host Disease (aGVHD) were presented at the 2018 International Society for Cell and Gene Therapy (ISCT) plenary breakout session held in Boston last week. Dr Kurtzberg described the properties of remestemcel-L that are relevant to understanding proposed mechanisms of action (MOA) in aGVHD, including sensing of damaging inflammatory mediators and consequent reduction in activation of immune cells.
NEW YORK and MELBOURNE, Australia, May 01, 2018-- Mesoblast’ s proprietary allogeneic cell technology platform was featured at the Unite to Cure Fourth International Vatican Conference on global healthcare ...
NEW YORK and MELBOURNE, Australia, April 18, 2018-- Mesoblast Limited today provided an update on the Phase 3 and Phase 2 b clinical trials of the Company's proprietary allogeneic mesenchymal precursor ...
NEW YORK and MELBOURNE, Australia, March 28, 2018-- Mesoblast Limited today announced that enrollment has completed in the Phase 3 trial evaluating a single intra-discal injection of its proprietary allogeneic ...
The early hope that stem cell therapy would make the paralysed walk, the blind see and cure diabetes have given way to a long list of failures, highlighted by early stem cell champion Geron Corp abandoning the field in 2011. Both have overcome major hurdles to manufacturing stem cell treatments on a large scale that are off-the-shelf products derived from healthy donor bone marrow and do not face immune system rejection issues. Australia's Mesoblast, with a market value of about $US500 million ($A652.86 million), is attempting to alter advanced heart failure, a leading cause of hospitalisations and deaths and an enormous cost burden.
NEW YORK & MELBOURNE, Australia--(BUSINESSWIRE)-- Mesoblast Limited has been named by Frost & Sullivan as the 2017 Global Technology Leader in the Cell Therapy Industry. Mesoblast is a biopharma company ...
Caterpillar, Avon Products, JA Solar Holdings, Mesoblast and 21Vianet Group highlighted as Zacks Bull and Bear of the Day
At Zacks, we suggest that investors pay close attention to our proven stock-picking system, which stresses the importance of earnings estimate revisions in finding winning stocks. But we also understand that lower-priced stocks often make attractive investments, and we will always cover stocks that are making newsworthy moves, big or small.